On World Ovarian Cancer Day, LGSOC Resource Guide Launches to Support People Living with Low-Grade Serous Ovarian Cancer STAAR Low-Grade Serous Ovarian Cancer Foundation, Not These Ovaries, and Verastem Oncology announced the launch of the LGSOC Resource Guide, a unique resource…
TRUQAP® (capivasertib)recommended by FDA Advisory Committee for PTEN-deficient metastatic hormone-sensitive prostate cancer The US Food and Drug Administration’s Oncologic Drugs Advisory Committee has recognized a favorable benefit risk profile for AstraZeneca’s TRUQAP® (capivasertib) in combination with abiraterone and androgen deprivation therapy…
Artera Secures CE Marking for Its AI Prostate and Breast Cancer Assays, Unlocking Global Expansion Artera, a developer of multimodal AI-based prognostic and predictive cancer tests, announced today that it was granted CE marking under the European Union In Vitro Diagnostic…
SAGA Diagnostics to Present New Pathlight™ MRD Data for Ovarian and Metastatic Breast Cancer at AACR 2026 SAGA Diagnostics, a pioneer in blood-based cancer detection and precision medicine redefining the standard for early molecular residual disease (MRD) detection, announced that the…
CatalYm Doses First Patient in Phase 2b Trial Evaluating Visugromab in Combination with Chemoimmunotherapy as Second-Line Treatment in Unresectable/Metastatic Hepatocellular Carcinoma CatalYm announced that the first patient has been dosed in the GDFATHER-HCC-01 trial The trial evaluates the company’s lead anti-GDF-15…
Almirall’s 17th Skin Academy Highlights Scientific Advances in Inflammatory Skin Diseases and Skin Cancer, Patient-Reported Outcomes, and Holistic Care in Medical Dermatology Almirall, a global biopharmaceutical company dedicated to medical dermatology, this weekend hosted the 17th edition of Skin Academy,…
ClearNote Health Appoints Jeffrey Venstrom, MD, as Chief Medical Officer and Expands Leadership Team to Drive Clinical Adoption of Early Cancer Detection Tests ClearNote Health, a company focused on improving early detection for some of the deadliest cancers, today announced…
Unite for HER and TOUCH, The Black Breast Cancer Alliance Present Pivotal Results for Black Breast Cancer Outcomes at 2025 San Antonio Breast Cancer Symposium Two leading breast cancer advocacy organizations, Unite for HER and TOUCH, The Black Breast Cancer…
Philanthropic organization has awarded $51.5 million in cancer research grants to date with one vision: cures in our lifetime. Curebound, a philanthropic organization dedicated to funding and advancing innovative cancer research, announced from San Diego that it has awarded 23…
Drug Farm, a private biotechnology company pioneering the use of genetics and artificial intelligence to discover and develop innovative immune-modulating therapies, announced today that it has entered into a Material Transfer Agreement (MTA) with Cincinnati Children’s Hospital Medical Center (CCHMC).…
Genentech’s Giredestrant Boosts PFS in ER+ Advanced Breast Cancer Genentech, a member of the Roche Group, announced encouraging results from the Phase III evERA study evaluating its investigational oral selective estrogen receptor degrader (SERD), giredestrant, in combination with everolimus. The…
NucleoBio, Corp., a biotechnology innovator in precision oncology diagnostics, has announced a new strategic collaboration with PreCheck Health Services, a high-complexity CLIA-certified and CAP-accredited clinical laboratory. The partnership will support the clinical development and processing of Prostac™, NucleoBio’s proprietary diagnostic…